Literature DB >> 19635100

Routinely diagnosed low-grade dysplasia in Barrett's oesophagus: a population-based study of natural history.

Piers Gatenby1, James Ramus, Christine Caygill, Neil Shepherd, Marc Winslet, Anthony Watson.   

Abstract

AIMS: To examine the natural history of columnar-lined oesophagus with routinely diagnosed low-grade dysplasia and ascertain the risk of oesophageal adenocarcinoma development. METHODS AND
RESULTS: A multicentre retrospective cohort study of 283 patients with low-grade dysplasia. Follow-up data were obtained from examination of hospital records. One hundred and forty-four patients had biopsies prior to low-grade dysplasia diagnosis and 217 had follow-up biopsies after index low-grade dysplasia diagnosis. In these patients the incidence of high-grade dysplasia and adenocarcinoma combined was 4.6% per annum and of adenocarcinoma alone was 2.7% per annum. At most recent follow-up, 43 (19.8%) had persistent low-grade dysplasia, 37 (17.1%) had changes indefinite for dysplasia and 108 (49.8%) had non-dysplastic columnar-lined oesophagus. When prevalent cases were excluded (those occurring within 1 year of index low-grade dysplasia diagnosis), the annual incidence of high-grade dysplasia and adenocarcinoma combined was 2.2% and of adenocarcinoma alone was 1.4%. The relative risk for adenocarcinoma development in low-grade dysplasia compared with non-dysplastic columnar-lined oesophagus was 2.871 (P = 0.002).
CONCLUSIONS: Low-grade dysplasia has a threefold increased risk of progression to cancer compared with non-dysplastic epithelium, but in the majority of patients dysplasia is not subsequently detected.

Entities:  

Mesh:

Year:  2009        PMID: 19635100     DOI: 10.1111/j.1365-2559.2009.03316.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  15 in total

Review 1.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

Review 2.  Disease Progression in Barrett's Low-Grade Dysplasia With Radiofrequency Ablation Compared With Surveillance: Systematic Review and Meta-Analysis.

Authors:  Bashar J Qumseya; Sachin Wani; Sherif Gendy; Ben Harnke; Jacques J Bergman; Herbert Wolfsen
Journal:  Am J Gastroenterol       Date:  2017-04-04       Impact factor: 10.864

3.  Management of Barrett's oesophagus and intramucosal oesophageal cancer: a review of recent development.

Authors:  Shanmugarajah Rajendra; Prateek Sharma
Journal:  Therap Adv Gastroenterol       Date:  2012-09       Impact factor: 4.409

Review 4.  Natural history of Barrett's esophagus.

Authors:  Rao Milind; Stephen E Attwood
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

5.  Heartburn, Barrett's oesophagus and cancer: implications for primary care.

Authors:  Anthony Watson; John Galloway
Journal:  Br J Gen Pract       Date:  2014-03       Impact factor: 5.386

Review 6.  Surveillance of Barrett's oesophagus: do we yet know whether it is worthwhile?

Authors:  Margaret Somerville; Martin Pitt
Journal:  Frontline Gastroenterol       Date:  2010-06-15

7.  Yield of Higher-Grade Neoplasia in Barrett's Esophagus With Low-Grade Dysplasia Is Double in the First Year Following Diagnosis.

Authors:  Joel H Rubenstein; Akbar K Waljee; Ben Dwamena; Jacques Bergman; Michael Vieth; Sachin Wani
Journal:  Clin Gastroenterol Hepatol       Date:  2018-01-04       Impact factor: 11.382

Review 8.  Barrett's oesophagus: Evidence from the current meta-analyses.

Authors:  Piers Gatenby; Yuen Soon
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

Review 9.  Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Thomas M Runge; Julian A Abrams; Nicholas J Shaheen
Journal:  Gastroenterol Clin North Am       Date:  2015-04-09       Impact factor: 3.806

Review 10.  Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis.

Authors:  Brian J Reid; Xiaohong Li; Patricia C Galipeau; Thomas L Vaughan
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.